Display options
Share it on

Int J Ophthalmol. 2016 Jun 18;9(6):858-62. doi: 10.18240/ijo.2016.06.12. eCollection 2016.

Peripheral retinal non-perfusion and treatment response in branch retinal vein occlusion.

International journal of ophthalmology

Kaveh Abri Aghdam, Lukas Reznicek, Mostafa Soltan Sanjari, Carsten Framme, Anna Bajor, Annemarie Klingenstein, Marcus Kernt, Florian Seidensticker

Affiliations

  1. Department of Ophthalmology, University Eye Hospital, Medical School of Hannover, Carl-Neuberg-Straße 1, Hannover 30625, Germany.
  2. Department of Ophthalmology, Ludwig Maximilians University, Mathildenstr. 8, Munich 80336, Germany.
  3. Eye Research Center, Rassoul Akram Hospital, Iran University of Medical Sciences, Sattarkhan-Niayesh Street, Tehran 14456-13131, Iran.
  4. Department of Ophthalmology, University Eye Hospital, Medical School of Hannover, Carl-Neuberg-Straße 1, Hannover 30625, Germany; Department of Ophthalmology, Ludwig Maximilians University, Mathildenstr. 8, Munich 80336, Germany.

PMID: 27366688 PMCID: PMC4916143 DOI: 10.18240/ijo.2016.06.12

Abstract

AIM: To evaluate the association between the size of peripheral retinal non-perfusion and the number of intravitreal ranibizumab injections in patients with treatment-naive branch retinal vein occlusion (BRVO) and macular edema.

METHODS: A total of 53 patients with treatment-naive BRVO and macular edema were included. Each patient underwent a full ophthalmologic examination including optical coherence tomography (OCT) imaging and ultra wide-field fluorescein angiography (UWFA). Monthly intravitreal ranibizumab injections were applied according to the recommendations of the German Ophthalmological Society. Two independent, masked graders quantified the areas of peripheral retinal non-perfusion.

RESULTS: Intravitreal injections improved best-corrected visual acuity (BCVA) significantly from 22.23±16.33 Early Treatment of Diabetic Retinopathy Study (ETDRS) letters to 36.23±15.19 letters (P<0.001), and mean central subfield thickness significantly reduced from 387±115 µm to 321±115 µm (P=0.01). Mean number of intravitreal ranibizumab injections was 3.61±1.56. The size of retinal non-perfusion correlated significantly with the number of intravitreal ranibizumab injections (R=0.724, P<0.001).

CONCLUSION: Peripheral retinal non-perfusion in patients with BRVO associates significantly with intravitreal ranibizumab injections in patients with BRVO and macular edema.

Keywords: angiography; branch retinal vein occlusion; non-perfusion; retina; wide-field

References

  1. Invest Ophthalmol Vis Sci. 2008 Oct;49(10):4297-302 - PubMed
  2. Curr Opin Ophthalmol. 2014 May;25(3):213-20 - PubMed
  3. Int Ophthalmol Clin. 2004 Fall;44(4):85-102 - PubMed
  4. Prog Retin Eye Res. 2005 Jul;24(4):493-519 - PubMed
  5. Retina. 2014 Sep;34(9):1736-42 - PubMed
  6. Clin Ophthalmol. 2013;7:389-94 - PubMed
  7. Retina. 2011 May;31(5):829-37 - PubMed
  8. Arch Ophthalmol. 2008 Apr;126(4):513-8 - PubMed
  9. Ophthalmology. 2013 Apr;120(4):795-802 - PubMed
  10. Br J Ophthalmol. 2012 May;96(5):694-8 - PubMed
  11. Arch Ophthalmol. 2002 Dec;120(12 ):1644-50 - PubMed
  12. Semin Ophthalmol. 2014 Mar;29(2):85-107 - PubMed
  13. Curr Eye Res. 2008 Feb;33(2):111-31 - PubMed
  14. Am J Ophthalmol. 2005 Sep;140(3):525-7 - PubMed
  15. Ophthalmic Surg Lasers Imaging. 2008 Jul-Aug;39(4):304-11 - PubMed
  16. Retina. 2012 Apr;32(4):785-91 - PubMed
  17. Graefes Arch Clin Exp Ophthalmol. 2014 May;252(5):745-52 - PubMed
  18. Surv Ophthalmol. 2011 Jul-Aug;56(4):281-99 - PubMed
  19. Ophthalmology. 2010 Apr;117(4):780-4 - PubMed
  20. Ophthalmology. 2010 Jun;117(6):1094-1101.e5 - PubMed
  21. Ophthalmology. 2005 Apr;112(4):540-7 - PubMed

Publication Types